A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults

Trial Profile

A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs MEDI 4920 (Primary)
  • Indications Sjogren's syndrome
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 17 Jun 2017 Results assessing the safety, pharmacokinetics, pharmacodynamics, and immunogenicity presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 18 May 2016 Status changed from active, no longer recruiting to completed.
    • 08 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top